CA-LASERFICHE
28.11.2023 16:01:35 CET | Business Wire | Press release
New research by Medical Group Management Association (MGMA) and Laserfiche — the leading SaaS provider of intelligent content management and business process automation — reveals that most healthcare organizations’ top priorities when considering integrative technologies are the elimination of manual work, mitigation of clinician/worker burnout and time savings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128977000/en/
Discover the opportunities and challenges for medical practice leaders in evaluating their platforms for workflow, electronic forms, document and records management and more. (Graphic: Business Wire)
“The healthcare industry has been disrupted by the growth of virtual visits, expectations for more personal, faster access to patients’ clinical results and care, plus the rise of AI,” said Grace Nam, strategic solutions manager, healthcare, at Laserfiche. “These trends have created a burgeoning challenge of managing, processing and leveraging an inundation of data that require cross-functional collaboration, and often include external organizations like labs and other physicians.”
The study surveyed medical practice administrators, physicians, billing and coding leaders and health information technology (HIT) workers for their views on electronic health records (EHR) or practice management (PM) systems, business automation and more. According to the report, most healthcare organizations are not looking to make a switch to a new EHR or PM system and nearly 80% of respondents rated their current EHR system as “very good” or “good.” However, when it came time to rate EHR systems’ individual attributes, those ratings dropped. Only half of respondents rated their EHR systems “very good” or “good” at saving time; 47% said they were very good or good at saving money; and only 40% said they were very good or good at mitigating clinician/worker burnout.
“Time-strapped organizations need integrated technologies to extract value from data without adding to the long list of manual tasks for already overwhelmed employees,” Nam added. “Investments in systems that enable business process automation while facilitating information governance are critical to healthcare organizations’ ability to leverage data and retain employees while providing a modern patient experience. Supporting the back office — including medical billing and coding, and working with third-party insurance companies — to boost speed and accuracy will be critical for on-time payments that impact revenue.”
“The business of healthcare and its future are tied directly to the ability to manage and make decisions based on data to support high-quality patient care,” the report states. “As the amount of data generated in healthcare grows about 47% a year, the need to manage the growing volumes of records in a secure, compliant fashion is unmistakable.”
To download a copy of the Intelligent Automation in Healthcare report, visit https://info.laserfiche.com/resource/intelligent-automation-healthcare.
To learn more about Laserfiche solutions for the healthcare industry, visit laserfiche.com/solutions/healthcare.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through workflows, e-forms, document management, integrations and analytics, the Laserfiche® platform centralizes information, structures clinical data and streamlines back-office processes so that healthcare professionals can focus on providing the highest standard of patient care.
For over 30 years, Laserfiche has served organizations in the healthcare industry as a trusted system for document and records management, enabling medical professionals to quickly retrieve records when needed, with robust security and compliance tools to support HIPAA compliance and patient confidentiality. By streamlining paperwork, information and data using digital forms and automated workflows, Laserfiche allows administration, clinicians and physicians to eliminate repetitive manual tasks, gain visibility into operations, support a holistic approach to patient care and focus on improving patient outcomes. Prebuilt solutions and integrations with industry-specific and common business applications further extend organizations’ digital transformation initiatives.
Today, Laserfiche’s cloud-first approach incorporates innovations in machine learning and AI, supporting healthcare organizations in empowering staff, streamlining the patient experience, supporting HIPAA compliance and providing the best possible patient experience.
Learn more at laserfiche.com/solutions/healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231128977000/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom